Cargando…
PHARAO-Studie: Arzneimittelversorgung entzündlich rheumatischer Erkrankungen: Leitliniengerechte Versorgung mit Biologika folgt Verfügbarkeit von Biosimilars
BACKGROUND: With the introduction of tumor necrosis factor (TNF) alpha inhibitors, the treatment of inflammatory rheumatic diseases (IRD) has undergone a fundamental change. Several of the originally high-priced biologics are now accessible as lower cost biosimilars, removing a significant impedimen...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Medizin
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627965/ https://www.ncbi.nlm.nih.gov/pubmed/36006471 http://dx.doi.org/10.1007/s00393-022-01259-5 |